Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Denardo

Showing results (181-190 of 274) with videos related to

Pageof 28
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 18, 1997
Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sourcesS M Lim, G L DeNardo, D A DeNardo, et al.
Cancer Biotherapy & Radiopharmaceuticals|April 2, 2003
Application of MINERVA Monte Carlo simulations to targeted radionuclide therapyMarie-Anne Descalle, Christine L Hartmann Siantar, Lucile Dauffy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Strategies for developing effective radioimmunotherapy for solid tumorsG L DeNardo, R T O'Donnell, L A Kroger, et al.
Journal of Neurosurgery|November 11, 1992
Cell-mediated immunity in severely head-injured patients: the role of suppressor lymphocytes and serum factorsK B Quattrocchi, C H Miller, F C Wagner, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 7, 2007
Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphomaOrazio Schillaci, Gerald L DeNardo, Sally J DeNardo, et al.
International Journal of Oncology|January 17, 2009
Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemiaG L DeNardo, G R Mirick, S Hok, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 18, 1999
Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemiaG L DeNardo, S J DeNardo, S Shen, et al.
The Prostate|July 25, 2000
Efficacy and toxicity of radioimmunotherapy with (90)Y-DOTA-peptide-ChL6 for PC3-tumored miceR T O'Donnell, S J DeNardo, G L DeNardo, et al.
Cancer|February 1, 1994
A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugatesD L Kukis, H Diril, D P Greiner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1997
Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignanciesK R Lamborn, G L DeNardo, S J DeNardo, et al.
Pageof 28

Showing results (181-190 of 274) with videos related to

Sort By:
Pageof 28
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 18, 1997
Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sourcesS M Lim, G L DeNardo, D A DeNardo, et al.
Cancer Biotherapy & Radiopharmaceuticals|April 2, 2003
Application of MINERVA Monte Carlo simulations to targeted radionuclide therapyMarie-Anne Descalle, Christine L Hartmann Siantar, Lucile Dauffy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Strategies for developing effective radioimmunotherapy for solid tumorsG L DeNardo, R T O'Donnell, L A Kroger, et al.
Journal of Neurosurgery|November 11, 1992
Cell-mediated immunity in severely head-injured patients: the role of suppressor lymphocytes and serum factorsK B Quattrocchi, C H Miller, F C Wagner, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 7, 2007
Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphomaOrazio Schillaci, Gerald L DeNardo, Sally J DeNardo, et al.
International Journal of Oncology|January 17, 2009
Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemiaG L DeNardo, G R Mirick, S Hok, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 18, 1999
Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemiaG L DeNardo, S J DeNardo, S Shen, et al.
The Prostate|July 25, 2000
Efficacy and toxicity of radioimmunotherapy with (90)Y-DOTA-peptide-ChL6 for PC3-tumored miceR T O'Donnell, S J DeNardo, G L DeNardo, et al.
Cancer|February 1, 1994
A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugatesD L Kukis, H Diril, D P Greiner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1997
Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignanciesK R Lamborn, G L DeNardo, S J DeNardo, et al.
Pageof 28